Biogen and partner Eisai said they were halting two late-stage clinical trials involving an experimental treatment for Alzheimer’s disease after determining it would likely fail to help patients.
The Phase 3 trials, ENGAGE and EMERGE, were designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia.
“This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience. We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly to this research,” said Michel Vounatsos, Chief Executive Officer at Biogen.
Read the press release.